Angelalign executive chairman Dai Feng discussed the company’s clinician‑driven approach, U.S. expansion plans and product development priorities in a recent interview with the original source. Feng described Angelalign’s founding culture — led by academic orthodontists — that deliberately targeted complex and extraction cases rather than only simple cosmetic treatments. He said that focus shaped product development and remains central as the company scales. Feng noted Angelalign is building clinician feedback loops into treatment planning, product development and customer support so dentists remain “in the command seat.” He also described a new Wisconsin manufacturing facility slated to come online in early 2027 and discussed ongoing patent litigation in the aligner space as a background challenge for scaling. (Source: the original source podcast interview with Dai Feng). Link: https://orthodonticproductsonline.com/resource-center/podcasts/a-conversation-with-dai-feng-inside-angelaligns-u-s-push/
What was reported: In the published conversation, Feng explained Angelalign’s philosophy of targeting difficult clinical cases, the company’s emphasis on clinician feedback in R&D and product updates, and plans for a U.S. manufacturing site in Wisconsin expected in early 2027. He also recounted the company’s culture of continuous product improvement and described efforts to retain individualized treatment planning at scale.
What this means for private practice: For orthodontists evaluating aligner systems, Angelalign’s messaging signals a continued emphasis on treatment planning flexibility and clinician control — features some practices prioritize for managing complex cases. The reported Wisconsin facility (expected early 2027) may affect U.S. manufacturing capacity and turnaround times if it comes online as described. Practices should assess clinical case fit, requested support features, and any regulatory or IP developments directly with Angelalign representatives before changing workflows. The interview is the primary source for these items; statements about timelines and litigation were reported by the company’s executive chairman in the podcast.